Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
2.860
+0.120 (4.38%)
Oct 26, 2026, 1:16 PM EDT - Market open
Upstream Bio Employees
Upstream Bio had 75 employees as of December 31, 2025. The number of employees increased by 23 or 44.23% compared to the previous year. That makes Upstream Bio the 33,158th largest employer in the world and 4,349th in the United States.
Employees
75
Change (1Y)
23
Growth (1Y)
44.23%
Revenue / Employee
$42,107
Profits / Employee
-$2,086,667
Market Cap
156.65M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75 | 23 | 44.23% |
| Dec 31, 2024 | 52 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Entrada Therapeutics | 152 |
| Coherus Oncology | 144 |
| Molecular Partners AG | 134 |
| Sutro Biopharma | 128 |
| MediWound | 121 |
| Acumen Pharmaceuticals | 61 |
| NovaBridge Biosciences | 30 |
UPB News
- 4 weeks ago - These beaten-down stocks could bounce back in January, if history is any guide - Market Watch
- 6 weeks ago - Upstream Bio presents results from VALIANT trial at ERS Congress - TheFly
- 6 weeks ago - Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 - GlobeNewsWire
- 7 weeks ago - Upstream Bio unveils Phase 3 plans for Verekitug in asthma, nasal polyps - TheFly
- 7 weeks ago - Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP - GlobeNewsWire
- 2 months ago - Upstream Bio price target lowered to $25 from $43 at Truist - TheFly
- 2 months ago - Upstream Bio price target raised to $9 from $8 at JPMorgan - TheFly
- 2 months ago - Upstream Bio price target lowered to $25 from $43 at Truist - TheFly